GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sera Prognostics Inc (NAS:SERA) » Definitions » Beneish M-Score

Sera Prognostics (Sera Prognostics) Beneish M-Score : -2.32 (As of May. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sera Prognostics's Beneish M-Score or its related term are showing as below:

SERA' s Beneish M-Score Range Over the Past 10 Years
Min: -2.32   Med: -1.19   Max: 453.85
Current: -2.32

During the past 5 years, the highest Beneish M-Score of Sera Prognostics was 453.85. The lowest was -2.32. And the median was -1.19.


Sera Prognostics Beneish M-Score Historical Data

The historical data trend for Sera Prognostics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Beneish M-Score Chart

Sera Prognostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - 453.85 -1.19 -2.32

Sera Prognostics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -1.13 -2.02 -2.30 -2.32

Competitive Comparison of Sera Prognostics's Beneish M-Score

For the Diagnostics & Research subindustry, Sera Prognostics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sera Prognostics's Beneish M-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sera Prognostics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sera Prognostics's Beneish M-Score falls into.



Sera Prognostics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sera Prognostics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.6433+0.528 * 0.892+0.404 * 1.6903+0.892 * 1.1418+0.115 * 0.6383
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6869+4.679 * -0.115747-0.327 * 1.7725
=-2.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $11.47 Mil.
Revenue was 0.041 + 0.042 + 0.123 + 0.1 = $0.31 Mil.
Gross Profit was 0.017 + -0.002 + 0.043 + 0.038 = $0.10 Mil.
Total Current Assets was $61.34 Mil.
Total Assets was $95.44 Mil.
Property, Plant and Equipment(Net PPE) was $2.00 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.90 Mil.
Selling, General, & Admin. Expense(SGA) was $24.69 Mil.
Total Current Liabilities was $24.44 Mil.
Long-Term Debt & Capital Lease Obligation was $0.84 Mil.
Net Income was -7.925 + -7.21 + -10.542 + -10.565 = $-36.24 Mil.
Non Operating Income was 0.361 + 0.514 + 0.595 + 0.523 = $1.99 Mil.
Cash Flow from Operations was -6.765 + -7.594 + -7.948 + -4.881 = $-27.19 Mil.
Total Receivables was $6.11 Mil.
Revenue was 0.065 + 0.087 + 0.078 + 0.038 = $0.27 Mil.
Gross Profit was 0.006 + 0.029 + 0.022 + 0.018 = $0.08 Mil.
Total Current Assets was $90.13 Mil.
Total Assets was $116.33 Mil.
Property, Plant and Equipment(Net PPE) was $3.06 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.76 Mil.
Selling, General, & Admin. Expense(SGA) was $31.48 Mil.
Total Current Liabilities was $15.54 Mil.
Long-Term Debt & Capital Lease Obligation was $1.85 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(11.47 / 0.306) / (6.113 / 0.268)
=37.48366 / 22.809701
=1.6433

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.075 / 0.268) / (0.096 / 0.306)
=0.279851 / 0.313725
=0.892

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (61.344 + 1.999) / 95.441) / (1 - (90.125 + 3.059) / 116.329)
=0.336312 / 0.198962
=1.6903

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.306 / 0.268
=1.1418

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.756 / (0.756 + 3.059)) / (0.9 / (0.9 + 1.999))
=0.198165 / 0.310452
=0.6383

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(24.692 / 0.306) / (31.483 / 0.268)
=80.69281 / 117.473881
=0.6869

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.84 + 24.443) / 95.441) / ((1.848 + 15.538) / 116.329)
=0.264907 / 0.149455
=1.7725

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-36.242 - 1.993 - -27.188) / 95.441
=-0.115747

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sera Prognostics has a M-score of -2.32 suggests that the company is unlikely to be a manipulator.


Sera Prognostics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sera Prognostics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sera Prognostics (Sera Prognostics) Business Description

Traded in Other Exchanges
N/A
Address
2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, and other pregnancy complications.
Executives
John J. Boniface officer: Chief Scientific Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson officer: General Counsel 320 WAKARA WAY, SALT LAKE CITY UT 84108
Austin Aerts officer: Chief Financial Officer 2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison officer: Chief Information Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley officer: Chief Medical Officer C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence director C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Zhenya Lindgardt director C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
Paul Kearney officer: Chief Data Officer 2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Blue Ox Healthcare Partners, Llc 10 percent owner 239 DAWSON ROAD, HILLSIDE NY 12529
Nichole L. Martin officer: VP OF Q/R & HIPPA PRIV. OFF C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Marcus Dean Wilson director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Joshua Phillips director C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Nadia Altomare officer: Chief Commercial Officer C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109

Sera Prognostics (Sera Prognostics) Headlines

From GuruFocus